Autoimmune Diseases  >>  tabalumab (LY2127399)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tabalumab (LY2127399) / Eli Lilly
NCT00785928 / 2008-004894-16: A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Checkmark
Apr 2013 - Apr 2013: 
Checkmark Data
Apr 2011 - Apr 2011: Data
Completed
2
158
US, Europe, RoW
LY2127399, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
01/10
12/10
NCT00689728 / 2008-001105-42: A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Checkmark P2 data
Dec 2012 - Dec 2012: P2 data
Checkmark Data
Apr 2011 - Apr 2011: Data
Completed
2
100
Canada, US, Europe, RoW
LY2127399, Placebo
Eli Lilly and Company
Arthritis, Rheumatoid
02/10
05/10
NCT00837811 / 2008-004875-23: An Open Label Extension Study in Participants With Rheumatoid Arthritis

Checkmark Rheumatoid Arthritis
Aug 2014 - Aug 2014: Rheumatoid Arthritis
Checkmark P2 data - ACR/ARHP 2012 (RA)
Sep 2012 - Sep 2012: P2 data - ACR/ARHP 2012 (RA)
Completed
2
182
US, Canada, Europe, RoW
LY2127399
Eli Lilly and Company
Rheumatoid Arthritis
01/11
01/12
NCT00882999 / 2008-007459-28: A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed
2
245
US, Europe, RoW
LY2127399, Placebo
Eli Lilly and Company
Relapsing-Remitting Multiple Sclerosis
02/11
06/12
NCT01576549: A Study of LY2127399 in Rheumatoid Arthritis

Terminated
2
2
US
LY2127399, tabalumab
Eli Lilly and Company
Rheumatoid Arthritis
05/13
05/13

Download Options